title: Acceptability of prophylactic human papillomavirus vaccination among adult men.
abstract: OBJECTIVE
  HPV vaccine acceptability was examined as part of a cohort study of HPV infection among adult males.
  
  
  RESULTS
  Overall, 69% of men reported that they were likely or very likely to be vaccinated against HPV if a prophylactic vaccine were available. Men most frequently cited side effects (69%), efficacy (65%), and safety (63%) as the major factors that would influence their decision to be vaccinated against HPV. Issues of vaccine costs and efficacy were important considerations for men of vaccine-eligible ages (18-26 years). Men who cited cost as a major factor in their HPV vaccine decisions and those indicating cost as a potential barrier had greater intention to be vaccinated. Heterosexual men had less intention to be vaccinated compared to men who have sex with men.
  
  
  METHODS
  Between July 2004 and June 2007, 445 adult males aged ≥18 years were enrolled primarily from a university-based population. A structured questionnaire addressed HPV vaccine awareness, attitudes, and intention to be vaccinated.
  
  
  CONCLUSIONS
  Acceptability of HPV vaccination among males is generally high. Costs and sexual history may influence vaccine utilization.
authors.affiliation: Cancer Research Center of Hawaii, University of Hawaii, Honolulu, HI, USA. brenda@crch.hawaii.edu
authors.forename: Brenda Y
authors.initials: BY
authors.lastname: Hernandez
authors.forename: Lynne R
authors.initials: LR
authors.lastname: Wilkens
authors.forename: Pamela J
authors.initials: PJ
authors.lastname: Thompson
authors.forename: Yurii B
authors.initials: YB
authors.lastname: Shvetsov
authors.forename: Marc T
authors.initials: MT
authors.lastname: Goodman
authors.forename: Lily
authors.initials: L
authors.lastname: Ning
authors.forename: Lana
authors.initials: L
authors.lastname: Kaopua
mesh_terms: D000328:Adult; D000368:Aged; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage*; D010342:Patient Acceptance of Health Care; D014611:Vaccination
chemical_list: D053918:Papillomavirus Vaccines